fcx-007
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02810951)
Timeline
Indications
Mechanism of action
- FibroblastsTissue restoration
tissue restoration - fibroblasts
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- fcx-007
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04213261 | Phase 3 | Jan 31, 2020 | Castle Creek Pharmaceuticals, Fibrocell Technologies, Inc. |
| NCT02810951 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2016 | Fibrocell Technologies, Inc., Intrexon, Stanford University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fibrocell Technologies, Inc. | For profit | 2 | 2 | 2 | 2016 |
| Castle Creek Pharmaceuticals | For profit | 1 | 0 | 1 | 2020 |
| Intrexon | For profit | 1 | 0 | 1 | 2016 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1